Effects of Anticholinergic Drugs on Cognitive Function in Older Australians: Results from the AIBL Study
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Background/Aims: The nature and extent of adverse cognitive effects due to the prescription of anticholinergic drugs in older people with and without dementia is unclear. Methods: We calculated the anticholinergic load (ACL) of medications taken by participants of the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of ageing, a cohort of 211 Alzheimer’s disease (AD) patients, 133 mild cognitive impairment (MCI) patients and 768 healthy controls (HC) all aged over 60 years. The association between ACL and cognitive function was examined for each diagnostic group (HC, MCI, AD). Results: A high ACL within the HC group was associated with significantly slower response speeds for the Stroop color and incongruent trials. No other significant relationships between ACL and cognition were noted. Conclusion: In this large cohort, prescribed anticholinergic drugs appeared to have modest effects upon psychomotor speed and executive function, but not on other areas of cognition in healthy older adults.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Winblad, B., Palmer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L. ‐., Nordberg, A., Bäckman, L., Albert, M., Almkvist, O., et al. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01380.x · Cited by 4,946
Ancelin, M. L., Artero, S., Portet, F., Dupuy, A.-M., Touchon, J., & Ritchie, K. (2006) · BMJ · doi:10.1136/bmj.38740.439664.de · Cited by 589
Cited by
The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease
Hampel, H., Mesulam, M.-M., Cuello, A. C., Farlow, M. R., Giacobini, E., Grossberg, G. T., Khachaturian, A. S., Vergallo, A., Cavedo, E., Snyder, P. J., et al. (2018) · Brain · doi:10.1093/brain/awy132 · Cited by 1,918
The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception
Weiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., Liu, E., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.05.1769 · Cited by 1,010
Salahudeen, M. S., Duffull, S. B., & Nishtala, P. S. (2015) · BMC Geriatrics · doi:10.1186/s12877-015-0029-9 · Cited by 547
Systematic review of anticholinergic risk scales in older adults
Durán, C. E., Azermai, M., & Vander Stichele, R. H. (2013) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-013-1499-3 · Cited by 369
“All these scales have demonstrated positive results in clinical settings [11–17].”
BackgroundResultRisacher, S. L., McDonald, B. C., Tallman, E. F., West, J. D., Farlow, M. R., Unverzagt, F. W., Gao, S., Boustani, M., Crane, P. K., Petersen, R. C., et al. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.0580 · Cited by 350
Weiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Cedarbaum, J., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.11.001 · Cited by 348
Salahudeen, M. S., Hilmer, S. N., & Nishtala, P. S. (2015) · Journal of the American Geriatrics Society · doi:10.1111/jgs.13206 · Cited by 189
Self-citationAnticholinergics: theoretical and clinical overview
Nishtala, P. S., Salahudeen, M. S., & Hilmer, S. N. (2016) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1165664 · Cited by 167
Self-citation
Metadata
- Authors
- Sittironnarit, G., Ames, D., Bush, A. I., Faux, N., Flicker, L., Foster, J., Hilmer, S., Lautenschlager, N. T., Maruff, P., Masters, C. L., Martins, R. N., Rowe, C., Szoeke, C., Ellis, K. A., & AIBL research group
- Venue
- Dementia and Geriatric Cognitive Disorders
- Publisher
- S. Karger AG
- Published
- 2011
- Volume
- 31
- Issue
- 3
- Pages
- 173-178
- ISSN
- 1420-8008 (ISSN-L)
- 1421-9824
- OpenAlex
- W2044191942
- Cited by
- 144
- References
- 2
- FWCI
- 2.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.